TNF and heart failure: Moreover, direct anti TNF-α therapies using specific antibodies did not ameliorate outcome in heart failure patients (e.g. infliximab: ATTACH trial [37], or eternecept: RENAISSANCE, RECOVER and RENEWAL trials [38]), while PTX treatment can benefit patients in the absence of a reduction of TNF-α levels [33].